Develops and commercializes orally administered anti-cancer small-molecule therapies, with a pipeline of clinical and preclinical candidates targeting solid tumors and hematologic malignancies. Serves patients with cancer, plus their families and caregivers, delivering therapies intended to improve outcomes and quality of life.